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Sir,
We thank Shastri and Stein for their interest in our work and we
appreciate the opportunity to clarify the issues raised by these
authors:
(1) As described in the MATERIALS AND METHODS section,
the study includes participants of screening colonoscopy.
Study participants who are covered by the statutory health
care system are typically aged 55 years or above corres-
ponding to the age at which screening colonoscopy is
offered by this health care modality. The small proportion
of study participants below the age of 55 (4.6%) years
includes people covered by private health insurance, or
people who undergo screening colonoscopy at their own
expense.
(2) The calculations of Shastri and Stein regarding the number of
screening colonoscopies performed in the gastroenterological
practices are strongly misleading for several reasons. First,
the recruitment of practices started in January 2006, but most
of them started to enrol patients at a later point of time. Some
practices also participated in recruitment only for a short time
period, but could not maintain their commitment because of
work overload or organisational matters. Thus, the average
recruitment period was considerably less than 2 years. Second,
not all people willing to participate in the study were eligible
for the present analyses (see inclusion and exclusion criteria).
Third, not all eligible people undergoing screening colono-
scopy were willing to participate in the study.
(3) Sufficient understanding of study information is an important
prerequisite to allow for an informed consent, which is a
fundamental principle of the Declaration of Helsinki. We
did not have the resources to offer the study information in
the variety of languages that would have been necessary to
overcome this exclusion criterion. We do not think, however,
that this point is of any relevance for our results, because only
a very small proportion of patients had to be excluded owing
to this criterion.
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